Mylan Ups Investment In Mapi’s Monthly Glatiramer
Puts Another $20m Into Candidate Undergoing Phase III Trials
Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.
You may also be interested in...
Mylan is teaming up with Israeli firm Mapi Pharma to develop and commercialise a long-acting glatiramer acetate product, Mapi’s ‘GA Depot’ candidate. Subject to approval from the Israeli Innovation Authority, the partnership sees Mylan acquire global marketing rights for the once-monthly injection for treating relapsingremitting multiple sclerosis (RRMS).
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.
Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.